Jauhn Etienne Villaruel

Article (news)

<div><span class="fr-img-caption fr-fic fr-dib" style="width:960px;display:block" width="960"><span class="fr-img-wrap"><img src="https://od2-image-api.abs-cbn.com/prod/editorImage/17701629935191767840987702anti-diabetic_cropped_processed_by_imagy.jpg" style="width:960px" class="fr-fic fr-dib" width="960"/><span class="fr-inner" style="text-align:left">This photograph taken on February 23, 2023, in Paris, shows the anti-diabetic medication Ozempic (semaglutide) made by Danish pharmaceutical company Novo Nordisk. Joel Saget, AFP<br/></span></span></span></div><div><br/></div><p>COPENHAGEN, Denmark — Danish pharmaceutical giant Novo Nordisk said Tuesday that it expects 2026 sales to slide by up to 13 percent as prices for its Ozempic and Wegovy anti-obesity drugs fall in the key US market.</p><div><a href="https://www.abs-cbn.com/news/health-science/2026/1/8/study-shows-how-fast-kilos-return-after-ending-weight-loss-drugs-1057">Study shows how fast kilos return after ending weight-loss drugs</a></div><p>Struggling in the face of growing competition, in particular from US rival Eli Lilly, Novo Nordisk also reported that its 2025 sales rose six percent in 2025 to 309 billion kronor ($48.9 billion), below the eight to 11 percent gain it had forecast in November.</p><p>The figure was still higher than the 307.6 billion kronor analyst consensus forecast calculated by Bloomberg.</p><p>Net profit edged one percent higher to 102.4 billion kroner ($16.2 billion).</p><p>Novo Nordisk said it expected this year&#x27;s sales to be between five and 13 percent lower, at constant exchange rates, than for 2025.</p><p>Last year had already been tough for the company that had until recently been Europe&#x27;s most valuable stock.</p><p>Growth slowed, forcing it to lower profit forecasts for four quarters in a row. Novo Nordisk also cut 9,000 jobs, which it announced had cost eight billion euros ($9.4 billion), and changed chief executive as it sought to turn around its fortunes.</p><p>&quot;The sales outlook is impacted by lower realized prices, including impacts related to the &#x27;Most Favored Nations&#x27; agreement in the US and the patent expiry of the semaglutide molecule&quot; in some markets, Novo Nordisk said. It also highlighted increased &quot;competition&quot;.</p><p>The company said that it expects the global market for GLP-1, as the hormone responsible for the weight loss is known, to continue to expand.</p><p>It said it would introduce new products such as the Wegovy pill and higher doses, &quot;enabling Novo Nordisk to continue to increase patient reach and expand volumes&quot;.</p><p>&quot;In 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market. However, we are very encouraged by the promising early uptake from the US launch of Wegovy pill,&quot; said chief executive officer Mike Doustar</p><p>Novo Nordisk received US regulatory approval for its first oral version of Wegovy in December and launched sales in January, and it noted most early prescriptions were being paid for by patients.</p><p>Novo Nordisk hopes to obtain a regulatory green light for its haemophilia treatment Mim8 and its next-generation obesity treatment CagriSema, its CEO said.</p><p>The group also announced the launch of a share buyback program worth up to 15 billion kroner.</p><div><br/></div><div><strong>© Agence France-Presse</strong></div><div><br/></div><div><br/></div><div><strong>RELATED VIDEO</strong></div><div><br/></div><div><strong><span class="fr-video fr-deletable fr-fvc fr-dvb fr-draggable" contenteditable="false" draggable="true"><iframe width="640" height="360" src="https://www.youtube.com/embed/yYYx19nW9-k?&amp;wmode=opaque&amp;rel=0" frameBorder="0" allowfullscreen="" class="fr-draggable"></iframe></span></strong><span class="fr-video fr-deletable fr-fvc fr-dvb fr-draggable" contenteditable="false" draggable="true"><iframe width="640" height="360" src="https://www.youtube.com/embed/O5YMo2IJrH4?&amp;wmode=opaque&amp;rel=0" frameBorder="0" allowfullscreen="" class="fr-draggable"></iframe></span><br/></div>

<p>Danish pharmaceutical giant Novo Nordisk said it expects 2026 sales to slide by up to 13 percent as prices for its Ozempic and Wegovy anti-obesity drugs fall in the key US market.</p>

Danish pharmaceutical giant Novo Nordisk said it expects 2026 sales to slide by up to 13 percent as prices for its Ozempic and Wegovy anti-obesity drugs fall in the key US market.

Ozempic maker Novo Nordisk forecasts 5 to 13 percent drop in 2026 sales

News

Entertainment

Lifestyle

Sports

Metro.Style

More

Sudoku

Word of the Day

Lotto

Horoscope

Health & Science

Ozempic maker Novo Nordisk forecasts 5 to 13 percent drop in 2026 sales

Etienne Fontaine,

Agence France-Presse

Published February 04, 2026 07:58 AM PHT

Read More:

Ozempic

Copenhagen

Denmark

pharmaceutical

earnings

novonordisk

Agence France-Presse

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

AI Policy

Terms of Service

Advertise with Us

© 2026 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2026 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2026 ABS-CBN Corporation. All Rights Reserved.